/PRNewswire/ Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today.
Study builds on clinical benefit reported in heavily pretreated MSS CRC patients with liver metastases treated with dual combination of COM701 and nivolumab Initial findings
On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG,
/PRNewswire/ Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target.
HOLON, Israel, Feb. 13, 2023 /PRNewswire/ Compugen Ltd. , a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will. | February 13, 2023